Donald Metcalf receives American Association for Cancer Research Lifetime Achievement Award

April 02, 2007

PHILADELPHIA - Donald Metcalf, M.D., the physiologist renowned as "the father of hematopoietic cytokines" for his pioneering work on the control of blood cell formation, will receive the American Association for Cancer Research Award for Lifetime Achievement in Cancer Research.

The award will be presented on Monday, April 16, 2007 during ceremonies at the AACR's Annual Meeting in Los Angeles, Calif.

In early studies, Dr. Metcalf discovered the function of the thymus gland in controlling the formation of lymphocytes, and beginning in 1965, co-developed a series of specialized culture techniques permitting the growth of various types of blood cells. These cultures led him and his team to the discovery of "colony-stimulating factors" (CSFs), hormones that control white blood cell formation and are, therefore, responsible for one's resistance to infection. His work, with that of others, led to the successful cloning of the genes for all mouse and human CSFs, and the mass production of these hormones by bacterial, yeast, and other cells for therapeutic use.

Dr. Metcalf's work provided the pivotal demonstration that CSFs, when injected into animals, stimulated the formation and regulated the activity of white blood cells. Exploiting this, his collaborators documented the effectiveness of GM-CSF and G-CSF (two primary white blood cell regulators) when injected into patients. These blood cell regulators have been in extensive clinical use since 1988 in the management of cancer patients following the use of chemotherapy or radiation therapy. CSF treatment accelerates hematopoietic regeneration in these patients, reducing the risk of infections, usefully shortening time of hospitalization, and permitting the delivery of increased doses of chemotherapy.

Furthermore, Dr. Metcalf and his colleagues showed that CSFs could elevate the levels of hematopoietic stem cells in the blood equivalent to levels in bone marrow. Not only was pheresis of peripheral blood a less traumatic and more prolific source of cells for transplantation, but the CSF-elicited stem cells achieved a more rapid recovery of white cell and platelet levels in patients. This dramatic advance has largely replaced bone marrow transplantation in cancer treatment and has had a major impact on the manner in which chemotherapy is used in cancer patients.

"As a world-renowned scientist and leader in the cancer research community, Dr. Metcalf is an outstanding choice for the AACR Award for Lifetime Achievement in Cancer Research," said Margaret Foti, Ph.D., M.D. (h.c.), AACR chief executive officer. "Dr. Metcalf's contributions to the field of hematology research have not only had a major impact in cancer research, but have also revolutionized our understanding of many other blood diseases.

Dr. Metcalf is the Carden Fellow in Cancer Research at the Walter and Eliza Hall Institute and Professor Emeritus, University of Melbourne, Australia. He received his B.Sc. in Virology (1951), his M.B.B.S. (1953), and his M.D. (1961) from the University of Sydney, Australia.

Dr. Metcalf has received numerous awards including the Albert Lasker Award, the Bristol-Myers Award, the Armand Hammer Prize, the Sloan Prize, and many others. In his native country, he has received the Gold Medal from the Australian Cancer Society, the Burnet Medal from the Australian Academy of Science, and the Prime Minister's Prize for Science, among others. In addition, he has been named an Officer and a Companion of the Order of Australia.

The AACR Award for Lifetime Achievement in Cancer Research was established and first presented in 2004 to honor an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether they have been in research, leadership, or mentorship, must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer.
-end-
Editors Note: To download a high-resolution photograph of Dr. Metcalf and for further information on this lectureship, please visit www.aacr.org.

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 70 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.

American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.